Sunshine Biopharma (SBFM) Stock Overview
Operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SBFM Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Sunshine Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.53 |
| 52 Week High | US$3.90 |
| 52 Week Low | US$1.17 |
| Beta | 0.33 |
| 1 Month Change | 12.92% |
| 3 Month Change | 4.08% |
| 1 Year Change | -51.74% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues
Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues
Jan 29Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch
Sep 12Sunshine Biopharma acquires Nora Pharma for C$30M
Oct 20We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth
Aug 08Sunshine Biopharma reports 1H results
Aug 04Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs
Apr 17Shareholder Returns
| SBFM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.8% | 5.2% | 1.2% |
| 1Y | -51.7% | -0.3% | 17.7% |
Return vs Industry: SBFM underperformed the US Biotechs industry which returned -0.3% over the past year.
Return vs Market: SBFM underperformed the US Market which returned 17.9% over the past year.
Price Volatility
| SBFM volatility | |
|---|---|
| SBFM Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SBFM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SBFM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 52 | Steve Slilaty | sunshinebiopharma.com |
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer.
Sunshine Biopharma, Inc. Fundamentals Summary
| SBFM fundamental statistics | |
|---|---|
| Market cap | US$6.97m |
| Earnings (TTM) | -US$6.31m |
| Revenue (TTM) | US$36.34m |
Is SBFM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBFM income statement (TTM) | |
|---|---|
| Revenue | US$36.34m |
| Cost of Revenue | US$24.23m |
| Gross Profit | US$12.11m |
| Other Expenses | US$18.42m |
| Earnings | -US$6.31m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 33.33% |
| Net Profit Margin | -17.35% |
| Debt/Equity Ratio | 0% |
How did SBFM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 11:29 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sunshine Biopharma, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Bouchey | Aegis Capital Corporation |